Protein-tyrosine kinases are important in regulation of growth and differentiation. They are oncogenic when mutated or inappropriately expressed. The mechanism of action of two tyrosine kinase growth factor receptors, the neu protein and the EGF receptor, will be investigated. These proteins are implicated in human breast and squamous cell cancer, respectively. Since they contribute directly to carcinogenesis and are cell surface proteins, they are important therapeutic targets. The present studies will elucidate the mechanism of signalling by tyrosine kinase growth factor receptors and aid in determining how they exert their effects on cells. 1.neu can be activated by a point mutation in the transmembrane domain. A sub-domain within the transmembrane domain has been identified in which second-site mutations inhibit the activity of this point mutation. This region will be further analyzed by site-directed mutation to determine whether it functions in normal signalling stimulated by hormone binding. 2.The oligomerization status of this panel of mutant proteins will be measured to determine whether the same sub-domain is required for neu protein oligomerization as a test of the clustering model for neu activation. 3.A single extra Cysteine residue introduced into the neu protein induces intermolecular crosslinks. These crosslinks will be moved along the molecule to determine whether certain intermolecular orientations activate the protein. 4.Information obtained above will be used to construct structural models for intermolecular interactions mediated by the transmembrane domain. 5.The neu protein and the EGF receptor cross-regulate one another. The mechanisms and consequences of these interactions will be investigated.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA045708-08
Application #
2091978
Study Section
Pathology B Study Section (PTHB)
Project Start
1987-07-01
Project End
1996-04-30
Budget Start
1995-05-01
Budget End
1996-04-30
Support Year
8
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Yale University
Department
Pathology
Type
Schools of Medicine
DUNS #
082359691
City
New Haven
State
CT
Country
United States
Zip Code
06520
Colavito, Sierra A; Zou, Mike R; Yan, Qin et al. (2014) Significance of glioma-associated oncogene homolog 1 (GLI1) expression in claudin-low breast cancer and crosstalk with the nuclear factor kappa-light-chain-enhancer of activated B cells (NF?B) pathway. Breast Cancer Res 16:444
Breindel, Jerrica L; Haskins, Jonathan W; Cowell, Elizabeth P et al. (2013) EGF receptor activates MET through MAPK to enhance non-small cell lung carcinoma invasion and brain metastasis. Cancer Res 73:5053-65
Bai, Yalai; Cheng, Huan; Bordeaux, Jennifer et al. (2013) Comparison of HER2 and phospho-HER2 expression between biopsy and resected breast cancer specimens using a quantitative assessment method. PLoS One 8:e79901
Held, Matthew A; Langdon, Casey G; Platt, James T et al. (2013) Genotype-selective combination therapies for melanoma identified by high-throughput drug screening. Cancer Discov 3:52-67
Stern, David F (2011) ""Competence"" progress. Mol Cell 42:411-2
Tworkoski, Kathryn; Singhal, Garima; Szpakowski, Sebastian et al. (2011) Phosphoproteomic screen identifies potential therapeutic targets in melanoma. Mol Cancer Res 9:801-12
Bai, Yalai; Tolles, Juliana; Cheng, Huan et al. (2011) Quantitative assessment shows loss of antigenic epitopes as a function of pre-analytic variables. Lab Invest 91:1253-61
Singhal, G; Akhter, M Z; Stern, D F et al. (2011) DNA triplex-mediated inhibition of MET leads to cell death and tumor regression in hepatoma. Cancer Gene Ther 18:520-30
Stern, David F (2010) EGFs and ERBBs--brief history and prospects. Semin Cell Dev Biol 21:917-21
Agarwal, S; Zerillo, C; Kolmakova, J et al. (2009) Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells. Br J Cancer 100:941-9

Showing the most recent 10 out of 54 publications